1. In Vivo
  2. >>Leadership

AI Driving Innovation: Insights From Exscientia CEO Andrew Hopkins

 
• By Lucie Ellis-Taitt and David Wild

Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead. 

AI drug development concept
• Source: Shutterstock

Founded back in 2012, Exscientia plc went public on Nasdaq in October 2021, raising over $300m – a huge amount for a biotech that is yet to bring a drug into the clinic on its own. However, it was ahead of the game being the first company to automate drug design and the first to have an AI-designed molecule enter clinical trials (albeit a partnered asset).

The company’s most advanced, wholly owned drugs are in IND-enabling studies. EXS74539 is a selective, reversible and brain penetrant LSD1...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By David Wild

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Execs On The Move: July 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Rising Leaders 2025: How Christina Smolke Turned Research Into Real World Impact

 
• By David Wild

The Stanford professor-turned-CEO's 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.

AI In The Loop: How Astellas Is Accelerating Oncology Drug Discovery

 
• By Jo Shorthouse

Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.

More from In Vivo

AI In The Loop: How Astellas Is Accelerating Oncology Drug Discovery

 
• By Jo Shorthouse

Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.

BioBytes: Israeli-US Startup Introduces Platform For Accelerated Clinical Data Analysis

 
• By David Wild

A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.

The Dementia Disparity: Rethinking Alzheimer’s Through The Female Lens

 
• By Ian Taylor

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.